Cancer Cell Inhibiting Sea Cucumber ( Holothuria leucospilota ) Protein as a Novel Anti-Cancer Drug

• Published in: Nutrients 2022-02, Vol.14 (4), p.786
• Main Authors: Ru, Ruizhen, Guo, Yanzheng, Mao, Juanxuan, Yu, Zonghe, Huang, Wen, Cao, Xudong, Hu, Huijian, Meng, Minjie, Yuan, Lihong
• Format: Article
• Language: English
• Subjects: Animals; anti-cancer activity; Antineoplastic Agents - pharmacology; Antioxidants; Apoptosis; Breast cancer; Cancer; Cancer therapies; cell apoptosis; Cell cycle; cell migration; Cell viability; Chinese medicine; Drug development; Drug resistance; Drugs; Flow cytometry; Holothuria; Holothuria leucospilota; Holothuroidea; Humans; Inflammation; Liver cancer; Lung cancer; marine extractions; Marine organisms; Neoplasms - drug therapy; Oxidants; Oxidizing agents; Peptides; Polysaccharides; Proteins; Raw materials; Reagents; Saccharides; Saponins; sea cucumber protein; Sea Cucumbers; targeted effects; Tumor cell lines; Tumors; Vegetables
• ISSN: 2072-6643; 2072-6643
• DOI: 10.3390/nu14040786

Cancer remains the primary cause of death worldwide. To develop less toxic anti-cancer drugs to relieve the suffering and improve the survival of cancer patients is the major focus in the anti-cancer field. To this end, marine creatures are being extensively studied for their anti-cancer effects, since extracts from at least 10% of the marine organisms have been shown to possess anti-tumor activities. As a classic Chinese traditional medicine, sea cucumbers and compounds extracted from the sea cucumbers, such as polysaccharides and saponins, have recently been shown to exhibit anti-cancer, anti-inflammatory, and anti-oxidant effects. ( ) is a tropical edible sea cucumber species that has been successfully cultivated and farmed in large scales, providing a readily available source of raw materials to support the development of novel marine anti-cancer drugs. However, very few studies have so far been performed on the biological activities of . In this study, we first investigated the anti-cancer effect of protein on three cancer cell lines (i.e., HepG2, A549, Panc02) and three normal cell lines (NIH-3T3, HaCaT, 16HBE). Our data showed that protein decreased the cell viabilities of HepG2, A549, HaCaT, 16HBE in a concentration-dependent manner, while Panc02 and NIH-3T3 in a time- and concentration-dependent manner. We also found that the inhibitory effect of protein (≥10 μg/mL) on cell viability is near or even superior to EPI, a clinical chemotherapeutic agent. In addition, our data also demonstrated that protein significantly affected the cell cycle and induced apoptosis in the three cancer cell lines investigated; in comparison, it showed no effects on the normal cell lines (i.e., NIH-3T3, HaCaT and 16HBE). Finally, our results also showed that protein exhibited the excellent performance in inhibiting cell immigrations. In conclusion, protein targeted the cancer cell cycles and induced cancer cell apoptosis; its superiority to inhibit cancer cell migration compared with EPI, shows the potential as a promising anti-cancer drug.